JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

JNJ

185.83

-0.68%↓

ABT

124.99

-1.16%↓

TMO

568.97

+1.87%↑

ISRG

539.52

-0.56%↓

DHR

218.13

-0.03%↓

Search

Codexis Inc

Abrir

SetorSaúde

2.52 -1.95

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.5

Máximo

2.73

Indicadores-chave

By Trading Economics

Rendimento

7.4M

-13M

Vendas

7.8M

15M

EPS

-0.16

Margem de lucro

-86.587

Funcionários

188

EBITDA

7.6M

-13M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+143.46% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

15M

247M

Abertura anterior

4.47

Fecho anterior

2.52

Sentimento de Notícias

By Acuity

50%

50%

154 / 373 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Codexis Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de out. de 2025, 23:50 UTC

Ações em Alta

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 de out. de 2025, 23:25 UTC

Ganhos

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 de out. de 2025, 23:18 UTC

Ganhos

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 de out. de 2025, 22:20 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 de out. de 2025, 22:13 UTC

Ganhos

Wal-Mart de Mexico Net Profit Falls in 3Q

28 de out. de 2025, 21:38 UTC

Ganhos

Correction to Visa Sales Jump Article

28 de out. de 2025, 21:17 UTC

Ganhos

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 de out. de 2025, 21:07 UTC

Ganhos

Visa Sales Jump as Consumers Keep Spending -- Update

28 de out. de 2025, 21:02 UTC

Ganhos

Mondelez Tempers Outlook as Costs Rise

28 de out. de 2025, 23:51 UTC

Conversa de Mercado

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 de out. de 2025, 23:42 UTC

Conversa de Mercado

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 de out. de 2025, 23:02 UTC

Ganhos

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 de out. de 2025, 23:01 UTC

Ganhos

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 de out. de 2025, 22:46 UTC

Ganhos

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 de out. de 2025, 22:45 UTC

Ganhos

SK Hynix 3Q Net KRW12.6T >000660.SE

28 de out. de 2025, 22:44 UTC

Ganhos

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 de out. de 2025, 22:43 UTC

Ganhos

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 de out. de 2025, 22:42 UTC

Ganhos

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 de out. de 2025, 22:40 UTC

Ganhos

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 de out. de 2025, 22:22 UTC

Ganhos

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 de out. de 2025, 22:20 UTC

Ganhos

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 de out. de 2025, 22:02 UTC

Ganhos

Review & Preview: Earnings Extravaganza -- Barrons.com

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

28 de out. de 2025, 21:42 UTC

Conversa de Mercado
Ganhos

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 de out. de 2025, 21:20 UTC

Ganhos

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 de out. de 2025, 21:19 UTC

Ganhos

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 de out. de 2025, 21:18 UTC

Ganhos

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Comparação entre Pares

Variação de preço

Codexis Inc Previsão

Preço-alvo

By TipRanks

143.46% parte superior

Previsão para 12 meses

Média 6.33 USD  143.46%

Máximo 11 USD

Mínimo 3 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Codexis Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

3

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.25 / 2.53Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

154 / 373 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat